Presentation Highlights: Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward looking statements that involve risks … Continued
Conference Call Highlights: Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward-looking statements that involve risks … Continued
Presentation Highlights: Net Sales increased 18.1% to $4.5 million Gross margin improved to 63.6% compared to 61.8% Net income grew to $386,553; 8.5% of net sales Don Pettigrew was appointed to President and Chief Commercial Officer on Spetmber 4th, 2018 This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited … Continued
Net Sales for the Quarter Ended September 30, 2018 Increased 18.1% Over the Same Period Last Year Gross Profit Increased 21.6% Over Third Quarter 2017 to $2.9 Million, or 63.6% of Net Sales Net Income Increased 45% Over Third Quarter 2017 to $386,553, or 8.5% of Net Sales Conference Call to Discuss Results October 24, … Continued
Liolis Gateway Presentation Highlights: Global leader in mechanical infusion systems Flagship FREEDOM60® system enables self-administered home infusion Part of the solution to today’s healthcare challenges New senior leadership focused on growth & value creation This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited to those related to the growth of … Continued
CHESTER, N.Y., Sept. 4, 2018 /PRNewswire/ — Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Donald B. Pettigrew has been appointed to the position of President and Chief Commercial Officer. Mr. Pettigrew comes to RMS following a 23-year career in the medical device industry, where he has vast experience and … Continued
CHESTER, N.Y., Aug. 27, 2018 /PRNewswire/ — Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Chairman and Interim President and Chief Executive Officer Dan Goldberger will be presenting at the 7th annual Liolis Gateway Conference taking place September 5-6, 2018 at the Four Seasons Hotel in San Francisco, California. The … Continued
RMS Medical Products Announces Record Quarterly Sales and Net Income – Net Sales for the quarter ended June 30, 2018 increased 17.6% over the same period last year – Net Income increased to $475,723 or 10.6% of Net Sales – Inaugural conference call August 7th at 9:00 AM ET CHESTER, N.Y., Aug. 6, 2018 /PRNewswire/ … Continued
• Quarterly Net Sales increased 17.6% over the comparable period. • Fifth consecutive quarter of Net Sales growth. • Announced appointment of Dan Goldberger as Chairman and interim Chief Executive Officer, replacing Andrew Sealfon. • Company to announce financial results for the quarter ended June 30, 2018 August 6th with accompanying conference call August 7th. … Continued
CHESTER, NY / April 9, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR; the “Company”) is pleased to announce that the United States Court of Appeals for the Federal Circuit shot down EMED’s appeal and that nine of the ten claims in EMED’s patent were invalid. Andy Sealfon, RMS Chief Executive … Continued
